NASDAQ: PHIOPhio Pharmaceuticals Corp Stock
$1.29-0.04 (-3.01%)
Updated Mar 14, 2025
PHIO Price
$1.29
Fair Value Price
N/A
Market Cap
$1.36M
52 Week Low
$1.22
52 Week High
$9.99
P/E
-0.12x
P/B
0.28x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.42M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.19
Operating Cash Flow
-$8M
Beta
0.8
Next Earnings
Mar 31, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PHIO Overview
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PHIO's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PHIO
Ranked#153 of 484
Ranked#153 of 484
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.84 | A | |
| $137.96 | A | |
| $8.16 | A |
Be the first to know about important PHIO news, forecast changes, insider trades & much more!
PHIO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PHIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PHIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PHIO is good value based on its book value relative to its share price (0.28x), compared to the US Biotechnology industry average (4.68x)
P/B vs Industry Valuation
PHIO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PHIO due diligence checks available for Premium users.
Valuation
PHIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
-118.09x
Market
3,446.57x
PHIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.28x
Industry
4.68x
PHIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PHIO's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.5M
Profit Margin
0%
PHIO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$5.9M
Liabilities
$919.0k
Debt to equity
0.19
PHIO's short-term assets ($5.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PHIO's short-term assets ($5.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PHIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PHIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
$0.0
Financing
$2.6M
PHIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PHIO vs Biotech Stocks
Phio Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.